<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.18.0&amp;ff=20231222090757&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_medium=rss&amp;v=2.18.0&amp;ff=20231222090757&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Fri, 22 Dec 2023 14:07:58 +0000</lastbuilddate>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>In Vivo Silencing of Regulatory Elements Using a Single AAV-CRISPRi Vector</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38131200/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Dec 22. doi: 10.1161/CIRCRESAHA.123.323854. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38131200/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38131200</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323854>10.1161/CIRCRESAHA.123.323854</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38131200</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>P Laurette</dc:creator>
<dc:creator>C Cao</dc:creator>
<dc:creator>D Ramanujam</dc:creator>
<dc:creator>M Schwaderer</dc:creator>
<dc:creator>T Lueneburg</dc:creator>
<dc:creator>S Kuss</dc:creator>
<dc:creator>L Weiss</dc:creator>
<dc:creator>R Dilshat</dc:creator>
<dc:creator>E E M Furlong</dc:creator>
<dc:creator>F Rezende</dc:creator>
<dc:creator>S Engelhardt</dc:creator>
<dc:creator>R Gilsbach</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>In Vivo Silencing of Regulatory Elements Using a Single AAV-CRISPRi Vector</dc:title>
<dc:identifier>pmid:38131200</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323854</dc:identifier>
</item>
<item>
<title>Using Genetics to Inform Interventions Related to Sodium and Potassium in Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38131187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>CONCLUSIONS: The data suggest that genetic risk in sodium and potassium pathways could be used in a precision medicine model to direct interventions more specifically in the management of hypertension. Intervention studies are warranted.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 22. doi: 10.1161/CIRCULATIONAHA.123.065394. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertension is a key risk factor for major adverse cardiovascular events but remains difficult to treat in many individuals. Dietary interventions are an effective approach to lower blood pressure (BP) but are not equally effective across all individuals. BP is heritable, and genetics may be a useful tool to overcome treatment response heterogeneity. We investigated whether the genetics of BP could be used to identify individuals with hypertension who may receive a particular benefit from lowering sodium intake and boosting potassium levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this observational genetic study, we leveraged cross-sectional data from up to 296 475 genotyped individuals drawn from the UK Biobank cohort for whom BP and urinary electrolytes (sodium and potassium), biomarkers of sodium and potassium intake, were measured. Biologically directed genetic scores for BP were constructed specifically among pathways related to sodium and potassium biology (pharmagenic enrichment scores), as well as unannotated genome-wide scores (conventional polygenic scores). We then tested whether there was a gene-by-environment interaction between urinary electrolytes and these genetic scores on BP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Genetic risk and urinary electrolytes both independently correlated with BP. However, urinary sodium was associated with a larger BP increase among individuals with higher genetic risk in sodium- and potassium-related pathways than in those with comparatively lower genetic risk. For example, each SD in urinary sodium was associated with a 1.47-mm Hg increase in systolic BP for those in the top 10% of the distribution of genetic risk in sodium and potassium transport pathways versus a 0.97-mm Hg systolic BP increase in the lowest 10% (<i>P</i>=1.95×10<sup>-</sup><sup>3</sup>). This interaction with urinary sodium remained when considering estimated glomerular filtration rate and indexing sodium to urinary creatinine. There was no strong evidence of an interaction between urinary sodium and a standard genome-wide polygenic score of BP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The data suggest that genetic risk in sodium and potassium pathways could be used in a precision medicine model to direct interventions more specifically in the management of hypertension. Intervention studies are warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38131187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38131187</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065394>10.1161/CIRCULATIONAHA.123.065394</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38131187</guid>
<pubDate>Fri, 22 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>William R Reay</dc:creator>
<dc:creator>Erin Clarke</dc:creator>
<dc:creator>Shaun Eslick</dc:creator>
<dc:creator>Carlos Riveros</dc:creator>
<dc:creator>Elizabeth G Holliday</dc:creator>
<dc:creator>Mark A McEvoy</dc:creator>
<dc:creator>Roseanne Peel</dc:creator>
<dc:creator>Stephen Hancock</dc:creator>
<dc:creator>Rodney J Scott</dc:creator>
<dc:creator>John R Attia</dc:creator>
<dc:creator>Clare E Collins</dc:creator>
<dc:creator>Murray J Cairns</dc:creator>
<dc:date>2023-12-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Using Genetics to Inform Interventions Related to Sodium and Potassium in Hypertension</dc:title>
<dc:identifier>pmid:38131187</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065394</dc:identifier>
</item>
<item>
<title>RAF-like protein kinases mediate a deeply conserved, rapid auxin response</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38128538/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>The plant-signaling molecule auxin triggers fast and slow cellular responses across land plants and algae. The nuclear auxin pathway mediates gene expression and controls growth and development in land plants, but this pathway is absent from algal sister groups. Several components of rapid responses have been identified in Arabidopsis, but it is unknown if these are part of a conserved mechanism. We recently identified a fast, proteome-wide phosphorylation response to auxin. Here, we show that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 13:S0092-8674(23)01275-8. doi: 10.1016/j.cell.2023.11.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The plant-signaling molecule auxin triggers fast and slow cellular responses across land plants and algae. The nuclear auxin pathway mediates gene expression and controls growth and development in land plants, but this pathway is absent from algal sister groups. Several components of rapid responses have been identified in Arabidopsis, but it is unknown if these are part of a conserved mechanism. We recently identified a fast, proteome-wide phosphorylation response to auxin. Here, we show that this response occurs across 5 land plant and algal species and converges on a core group of shared targets. We found conserved rapid physiological responses to auxin in the same species and identified rapidly accelerated fibrosarcoma (RAF)-like protein kinases as central mediators of auxin-triggered phosphorylation across species. Genetic analysis connects this kinase to both auxin-triggered protein phosphorylation and rapid cellular response, thus identifying an ancient mechanism for fast auxin responses in the green lineage.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38128538/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38128538</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.021>10.1016/j.cell.2023.11.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38128538</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Andre Kuhn</dc:creator>
<dc:creator>Mark Roosjen</dc:creator>
<dc:creator>Sumanth Mutte</dc:creator>
<dc:creator>Shiv Mani Dubey</dc:creator>
<dc:creator>Vanessa Polet Carrillo Carrasco</dc:creator>
<dc:creator>Sjef Boeren</dc:creator>
<dc:creator>Aline Monzer</dc:creator>
<dc:creator>Jasper Koehorst</dc:creator>
<dc:creator>Takayuki Kohchi</dc:creator>
<dc:creator>Ryuichi Nishihama</dc:creator>
<dc:creator>Matyáš Fendrych</dc:creator>
<dc:creator>Joris Sprakel</dc:creator>
<dc:creator>Jiří Friml</dc:creator>
<dc:creator>Dolf Weijers</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>RAF-like protein kinases mediate a deeply conserved, rapid auxin response</dc:title>
<dc:identifier>pmid:38128538</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.021</dc:identifier>
</item>
<item>
<title>Metabolic regulation of homologous recombination repair by MRE11 lactylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38128537/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>Lactylation is a lactate-induced post-translational modification best known for its roles in epigenetic regulation. Herein, we demonstrate that MRE11, a crucial homologous recombination (HR) protein, is lactylated at K673 by the CBP acetyltransferase in response to DNA damage and dependent on ATM phosphorylation of the latter. MRE11 lactylation promotes its binding to DNA, facilitating DNA end resection and HR. Inhibition of CBP or LDH downregulated MRE11 lactylation, impaired HR, and enhanced...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 18:S0092-8674(23)01276-X. doi: 10.1016/j.cell.2023.11.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Lactylation is a lactate-induced post-translational modification best known for its roles in epigenetic regulation. Herein, we demonstrate that MRE11, a crucial homologous recombination (HR) protein, is lactylated at K673 by the CBP acetyltransferase in response to DNA damage and dependent on ATM phosphorylation of the latter. MRE11 lactylation promotes its binding to DNA, facilitating DNA end resection and HR. Inhibition of CBP or LDH downregulated MRE11 lactylation, impaired HR, and enhanced chemosensitivity of tumor cells in patient-derived xenograft and organoid models. A cell-penetrating peptide that specifically blocks MRE11 lactylation inhibited HR and sensitized cancer cells to cisplatin and PARPi. These findings unveil lactylation as a key regulator of HR, providing fresh insights into the ways in which cellular metabolism is linked to DSB repair. They also imply that the Warburg effect can confer chemoresistance through enhancing HR and suggest a potential therapeutic strategy of targeting MRE11 lactylation to mitigate the effects.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38128537/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38128537</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.022>10.1016/j.cell.2023.11.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38128537</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Yuping Chen</dc:creator>
<dc:creator>Jinhuan Wu</dc:creator>
<dc:creator>Linhui Zhai</dc:creator>
<dc:creator>Tingting Zhang</dc:creator>
<dc:creator>Hui Yin</dc:creator>
<dc:creator>Huanyao Gao</dc:creator>
<dc:creator>Fei Zhao</dc:creator>
<dc:creator>Zhe Wang</dc:creator>
<dc:creator>Xiaoning Yang</dc:creator>
<dc:creator>Mingpeng Jin</dc:creator>
<dc:creator>Bingsong Huang</dc:creator>
<dc:creator>Xin Ding</dc:creator>
<dc:creator>Rui Li</dc:creator>
<dc:creator>Jie Yang</dc:creator>
<dc:creator>Yiming He</dc:creator>
<dc:creator>Qianwen Wang</dc:creator>
<dc:creator>Weibin Wang</dc:creator>
<dc:creator>Jake A Kloeber</dc:creator>
<dc:creator>Yunxuan Li</dc:creator>
<dc:creator>Bingbing Hao</dc:creator>
<dc:creator>Yuanyuan Zhang</dc:creator>
<dc:creator>Jiadong Wang</dc:creator>
<dc:creator>Minjia Tan</dc:creator>
<dc:creator>Ke Li</dc:creator>
<dc:creator>Ping Wang</dc:creator>
<dc:creator>Zhenkun Lou</dc:creator>
<dc:creator>Jian Yuan</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Metabolic regulation of homologous recombination repair by MRE11 lactylation</dc:title>
<dc:identifier>pmid:38128537</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.022</dc:identifier>
</item>
<item>
<title>Correction to: Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38127058/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 21:ehad855. doi: 10.1093/eurheartj/ehad855. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38127058/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38127058</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad855>10.1093/eurheartj/ehad855</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38127058</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:date>2023-12-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry</dc:title>
<dc:identifier>pmid:38127058</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad855</dc:identifier>
</item>
<item>
<title>A conundrum of arterialized capillaries and vascular dilation in chronic limb-threatening ischaemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38126898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 21:ehad826. doi: 10.1093/eurheartj/ehad826. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38126898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38126898</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad826>10.1093/eurheartj/ehad826</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38126898</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Vijay C Ganta</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:creator>Brian H Annex</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A conundrum of arterialized capillaries and vascular dilation in chronic limb-threatening ischaemia</dc:title>
<dc:identifier>pmid:38126898</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad826</dc:identifier>
</item>
<item>
<title>Induced Endothelial Cell CycleArrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38126211/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>CONCLUSIONS: This study provides new insights into molecular mechanisms leading to HHT by defining how endothelial cell cycle is dysregulated in AVMs because of BMP9/10 and Alk1 signaling deficiencies, and how restoration of endothelial cell cycle control may be used to treat AVMs in patients with HHT.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 21. doi: 10.1161/CIRCULATIONAHA.122.062952. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Distinct endothelial cell cycle states (early G1 versus late G1) provide different "windows of opportunity" to enable the differential expression of genes that regulate venous versus arterial specification, respectively. Endothelial cell cycle control and arteriovenous identities are disrupted in vascular malformations including arteriovenous shunts, the hallmark of hereditary hemorrhagic telangiectasia (HHT). To date, the mechanistic link between endothelial cell cycle regulation and the development of arteriovenous malformations (AVMs) in HHT is not known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used BMP (bone morphogenetic protein) 9/10 blocking antibodies and endothelial-specific deletion of activin A receptor like type 1 (<i>Alk1</i>) to induce HHT in Fucci (fluorescent ubiquitination-based cell cycle indicator) 2 mice to assess endothelial cell cycle states in AVMs. We also assessed the therapeutic potential of inducing endothelial cell cycle G1 arrest in HHT to prevent AVMs by repurposing the Food and Drug Administration-approved CDK (cyclin-dependent kinase) 4/6 inhibitor (CDK4/6i) palbociclib.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that endothelial cell cycle state and associated gene expressions are dysregulated during the pathogenesis of vascular malformations in HHT. We also showed that palbociclib treatment prevented AVM development induced by BMP9/10 inhibition and <i>Alk1</i> genetic deletion. Mechanistically, endothelial cell late G1 arrest induced by palbociclib modulates the expression of genes regulating arteriovenous identity, endothelial cell migration, metabolism, and VEGF-A (vascular endothelial growth factor A) and BMP9 signaling that collectively contribute to the prevention of vascular malformations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study provides new insights into molecular mechanisms leading to HHT by defining how endothelial cell cycle is dysregulated in AVMs because of BMP9/10 and Alk1 signaling deficiencies, and how restoration of endothelial cell cycle control may be used to treat AVMs in patients with HHT.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38126211/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38126211</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.062952>10.1161/CIRCULATIONAHA.122.062952</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38126211</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Gael Genet</dc:creator>
<dc:creator>Nafiisha Genet</dc:creator>
<dc:creator>Umadevi Paila</dc:creator>
<dc:creator>Shelby R Cain</dc:creator>
<dc:creator>Aleksandra Cwiek</dc:creator>
<dc:creator>Nicholas W Chavkin</dc:creator>
<dc:creator>Vlad Serbulea</dc:creator>
<dc:creator>Agnès Figueras</dc:creator>
<dc:creator>Pau Cerdà</dc:creator>
<dc:creator>Stephanie P McDonnell</dc:creator>
<dc:creator>Danya Sankaranarayanan</dc:creator>
<dc:creator>Mahalia Huba</dc:creator>
<dc:creator>Elizabeth A Nelson</dc:creator>
<dc:creator>Antoni Riera-Mestre</dc:creator>
<dc:creator>Karen K Hirschi</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Induced Endothelial Cell CycleArrest Prevents Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia</dc:title>
<dc:identifier>pmid:38126211</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.062952</dc:identifier>
</item>
<item>
<title>Single-Cell RNA Sequencing Reveals Metabolic Stress-Dependent Activation of Cardiac Macrophages in a Model of Dyslipidemia-Induced Diastolic Dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38126199/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>CONCLUSIONS: Using single-cell RNA sequencing , in a model of diastolic dysfunction driven by hyperlipidemia, we have determined the effects of metabolic distress on cardiac inflammatory cells, in particular on macrophages, and suggest sodium glucose cotransporter-2 inhibitors as potential therapeutic agents for the targeting of a specific phenotype of HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 21. doi: 10.1161/CIRCULATIONAHA.122.062984. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Metabolic distress is often associated with heart failure with preserved ejection fraction (HFpEF) and represents a therapeutic challenge. Metabolism-induced systemic inflammation links comorbidities with HFpEF. How metabolic changes affect myocardial inflammation in the context of HFpEF is not known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We found that ApoE knockout mice fed a Western diet recapitulate many features of HFpEF. Single-cell RNA sequencing was used for expression analysis of CD45<sup>+</sup> cardiac cells to evaluate the involvement of inflammation in diastolic dysfunction. We focused bioinformatics analysis on macrophages, obtaining high-resolution identification of subsets of these cells in the heart, enabling us to study the outcomes of metabolic distress on the cardiac macrophage infiltrate and to identify a macrophage-to-cardiomyocyte regulatory axis. To test whether a clinically relevant sodium glucose cotransporter-2 inhibitor could ameliorate the cardiac immune infiltrate profile in our model, mice were randomized to receive the sodium glucose cotransporter-2 inhibitor dapagliflozin or vehicle for 8 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ApoE knockout mice fed a Western diet presented with reduced diastolic function, reduced exercise tolerance, and increased pulmonary congestion associated with cardiac lipid overload and reduced polyunsaturated fatty acids. The main immune cell types infiltrating the heart included 4 subpopulations of resident and monocyte-derived macrophages, determining a proinflammatory profile exclusively in ApoE knockout- Western diet mice. Lipid overload had a direct effect on inflammatory gene activation in macrophages, mediated through endoplasmic reticulum stress pathways. Investigation of the macrophage-to-cardiomyocyte regulatory axis revealed the potential effects on cardiomyocytes of multiple inflammatory cytokines secreted by macrophages, affecting pathways such as hypertrophy, fibrosis, and autophagy. Finally, we describe an anti-inflammatory effect of sodium glucose cotransporter-2 inhibitor in this model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Using single-cell RNA sequencing , in a model of diastolic dysfunction driven by hyperlipidemia, we have determined the effects of metabolic distress on cardiac inflammatory cells, in particular on macrophages, and suggest sodium glucose cotransporter-2 inhibitors as potential therapeutic agents for the targeting of a specific phenotype of HFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38126199/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38126199</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.062984>10.1161/CIRCULATIONAHA.122.062984</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38126199</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Cristina Panico</dc:creator>
<dc:creator>Arianna Felicetta</dc:creator>
<dc:creator>Paolo Kunderfranco</dc:creator>
<dc:creator>Marco Cremonesi</dc:creator>
<dc:creator>Nicolò Salvarani</dc:creator>
<dc:creator>Pierluigi Carullo</dc:creator>
<dc:creator>Federico Colombo</dc:creator>
<dc:creator>Alessandra Idini</dc:creator>
<dc:creator>Mauro Passaretti</dc:creator>
<dc:creator>Riccardo Doro</dc:creator>
<dc:creator>Marcello Rubino</dc:creator>
<dc:creator>Alessandro Villaschi</dc:creator>
<dc:creator>Giorgio Da Rin</dc:creator>
<dc:creator>Clelia Peano</dc:creator>
<dc:creator>Marinos Kallikourdis</dc:creator>
<dc:creator>Carolina M Greco</dc:creator>
<dc:creator>Gianluigi Condorelli</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Single-Cell RNA Sequencing Reveals Metabolic Stress-Dependent Activation of Cardiac Macrophages in a Model of Dyslipidemia-Induced Diastolic Dysfunction</dc:title>
<dc:identifier>pmid:38126199</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.062984</dc:identifier>
</item>
<item>
<title>Ago2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38126189/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>CONCLUSIONS: Our findings reveal that the SIRT3-Ago2-CYTB axis links glucotoxicity to cardiac electron transport chain imbalance, providing new mechanistic insights and the basis to develop mitochondria targeting therapies for diabetic cardiomyopathy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 21. doi: 10.1161/CIRCULATIONAHA.123.065546. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Diabetes is associated with cardiovascular complications. microRNAs translocate into subcellular organelles to modify genes involved in diabetic cardiomyopathy. However, functional properties of subcellular Ago2 (Argonaute2), a core member of miRNA machinery, remain elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We elucidated the function and mechanism of subcellular localized Ago2 on mouse models for diabetes and diabetic cardiomyopathy. Recombinant adeno-associated virus type 9 was used to deliver Ago2 to mice through the tail vein. Cardiac structure and functions were assessed by echocardiography and catheter manometer system.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Ago2 was decreased in mitochondria of diabetic cardiomyocytes. Overexpression of mitochondrial Ago2 attenuated diabetes-induced cardiac dysfunction. Ago2 recruited <i>TUFM</i>, a mitochondria translation elongation factor, to activate translation of electron transport chain subunits and decrease reactive oxygen species. Malonylation, a posttranslational modification of Ago2, reduced the importing of Ago2 into mitochondria in diabetic cardiomyopathy. Ago2 malonylation was regulated by a cytoplasmic-localized short isoform of <i>SIRT3</i> through a previously unknown demalonylase function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings reveal that the <i>SIRT3</i>-Ago2-<i>CYTB</i> axis links glucotoxicity to cardiac electron transport chain imbalance, providing new mechanistic insights and the basis to develop mitochondria targeting therapies for diabetic cardiomyopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38126189/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38126189</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065546>10.1161/CIRCULATIONAHA.123.065546</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38126189</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jiabing Zhan</dc:creator>
<dc:creator>Kunying Jin</dc:creator>
<dc:creator>Rong Xie</dc:creator>
<dc:creator>Jiahui Fan</dc:creator>
<dc:creator>Yuyan Tang</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:creator>Huaping Li</dc:creator>
<dc:creator>Dao Wen Wang</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ago2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation</dc:title>
<dc:identifier>pmid:38126189</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065546</dc:identifier>
</item>
<item>
<title>Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38124672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 21;44(48):5092-5094. doi: 10.1093/eurheartj/ehad746.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38124672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38124672</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad746>10.1093/eurheartj/ehad746</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38124672</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Huda Abu-Own</dc:creator>
<dc:creator>Ian Webb</dc:creator>
<dc:creator>Darlington O Okonko</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes</dc:title>
<dc:identifier>pmid:38124672</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad746</dc:identifier>
</item>
<item>
<title>Sodium-glucose cotransporter 2 inhibitors, weight loss therapies, and ferric carboxymaltose: new light shed on innovative ways to reduce cardiovascular risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38124671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 21;44(48):5009-5014. doi: 10.1093/eurheartj/ehad815.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38124671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38124671</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad815>10.1093/eurheartj/ehad815</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38124671</guid>
<pubDate>Thu, 21 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-12-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sodium-glucose cotransporter 2 inhibitors, weight loss therapies, and ferric carboxymaltose: new light shed on innovative ways to reduce cardiovascular risk</dc:title>
<dc:identifier>pmid:38124671</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad815</dc:identifier>
</item>
<item>
<title>Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38117483/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: In stabilized patients with AMI, the ischemic and bleeding outcomes of an unguided de-escalation strategy with clopidogrel compared with a ticagrelor-based DAPT strategy were consistent without significant interaction, regardless of the presence of high ischemic risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 20:e234587. doi: 10.1001/jamacardio.2023.4587. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: In patients with acute myocardial infarction (AMI) who have high ischemic risk, data on the efficacy and safety of the de-escalation strategy of switching from ticagrelor to clopidogrel are lacking.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the outcomes of the de-escalation strategy compared with dual antiplatelet therapy (DAPT) with ticagrelor in stabilized patients with AMI and high ischemic risk following percutaneous coronary intervention (PCI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction (TALOS-AMI) trial, an open-label, assessor-blinded, multicenter, randomized clinical trial. Patients with AMI who had no event during 1 month of ticagrelor-based DAPT after PCI were included. High ischemic risk was defined as having a history of diabetes or chronic kidney disease, multivessel PCI, at least 3 lesions treated, total stent length greater than 60 mm, at least 3 stents implanted, left main PCI, or bifurcation PCI with at least 2 stents. Data were collected from February 14, 2014, to January 21, 2021, and analyzed from December 1, 2021, to June 30, 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Patients were randomly assigned to either de-escalation from ticagrelor to clopidogrel or ticagrelor-based DAPT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Ischemic outcomes (composite of cardiovascular death, myocardial infarction, ischemic stroke, ischemia-driven revascularization, or stent thrombosis) and bleeding outcomes (Bleeding Academic Research Consortium type 2, 3, or 5 bleeding) were evaluated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 2697 patients with AMI (mean [SD] age, 60.0 [11.4] years; 454 [16.8%] female), 1371 (50.8%; 684 assigned to de-escalation and 687 assigned to ticagrelor-based DAPT) had high ischemic risk features and a significantly higher risk of ischemic outcomes than those without high ischemic risk (1326 patients [49.2%], including 665 assigned to de-escalation and 661 assigned to ticagrelor-based DAPT) (hazard ratio [HR], 1.74; 95% CI, 1.15-2.63; P = .01). De-escalation to clopidogrel, compared with ticagrelor-based DAPT, showed no significant difference in ischemic risk across the high ischemic risk group (HR, 0.88; 95% CI, 0.54-1.45; P = .62) and the non-high ischemic risk group (HR, 0.65; 95% CI, 0.33-1.28; P = .21), without heterogeneity (P for interaction = .47). The bleeding risk of the de-escalation group was consistent in both the high ischemic risk group (HR, 0.64; 95% CI, 0.37-1.11; P = .11) and the non-high ischemic risk group (HR, 0.42; 95% CI, 0.24-0.75; P = .003), without heterogeneity (P for interaction = .32).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In stabilized patients with AMI, the ischemic and bleeding outcomes of an unguided de-escalation strategy with clopidogrel compared with a ticagrelor-based DAPT strategy were consistent without significant interaction, regardless of the presence of high ischemic risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38117483/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38117483</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC10733848/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">PMC10733848</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4587>10.1001/jamacardio.2023.4587</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38117483</guid>
<pubDate>Wed, 20 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Myunhee Lee</dc:creator>
<dc:creator>Sungwook Byun</dc:creator>
<dc:creator>Sungmin Lim</dc:creator>
<dc:creator>Eun Ho Choo</dc:creator>
<dc:creator>Kwan Yong Lee</dc:creator>
<dc:creator>Donggyu Moon</dc:creator>
<dc:creator>Ik Jun Choi</dc:creator>
<dc:creator>Byung-Hee Hwang</dc:creator>
<dc:creator>Chan Joon Kim</dc:creator>
<dc:creator>Mahn-Won Park</dc:creator>
<dc:creator>Yun Seok Choi</dc:creator>
<dc:creator>Hee-Yeol Kim</dc:creator>
<dc:creator>Ki-Dong Yoo</dc:creator>
<dc:creator>Doo-Soo Jeon</dc:creator>
<dc:creator>Hyeon Woo Yim</dc:creator>
<dc:creator>Kiyuk Chang</dc:creator>
<dc:creator>TALOS-AMI Investigators</dc:creator>
<dc:date>2023-12-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38117483</dc:identifier>
<dc:identifier>pmc:PMC10733848</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4587</dc:identifier>
</item>
<item>
<title>Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38117227/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>CONCLUSIONS: This observational study suggests that the benefits and risks of continuing OAC therapy after CA for AF differ based on the patient's CHADS2 score. The risk of major bleeding due to OAC continuation seems to outweigh the risk reduction of thromboembolism in patients with lower thromboembolic risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 20:ehad798. doi: 10.1093/eurheartj/ehad798. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Few recent large-scale studies have evaluated the risks and benefits of continuing oral anticoagulant (OAC) therapy after catheter ablation (CA) for atrial fibrillation (AF). This study evaluated the status of continuation of OAC therapy and the association between continuation of OAC therapy and thromboembolic and bleeding events according to the CHADS2 score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This retrospective study included data from the Japanese nationwide administrative claims database of patients who underwent CA for AF between April 2014 and March 2021. Patients without AF recurrence assessed by administrative data of the treatment modalities were divided into two groups according to continuation of OAC therapy 6 months after the index CA. The primary outcomes were thromboembolism and major bleeding after a landmark period of 6 months. After inverse probability of treatment weighting analysis, the association between OAC continuation and outcomes was determined according to the CHADS2 score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 231 374 patients included, 69.7%, 21.6%, and 8.7% had CHADS2 scores of ≤1, 2, and ≥3, respectively. Of these, 71% continued OAC therapy at 6 months. The OAC continuation rate was higher in the high CHADS2 score group than that in the low CHADS2 score group. Among all patients, 2451 patients (0.55 per 100 person-years) had thromboembolism and 2367 (0.53 per 100 person-years) had major bleeding. In the CHADS2 score ≤1 group, the hazard ratio of the continued OAC group was 0.86 [95% confidence interval (CI): 0.74-1.01, P = .06] for thromboembolism and was 1.51 (95% CI: 1.27-1.80, P &lt; .001) for major bleeding. In the CHADS2 score ≥3 group, the hazard ratio of the continued OAC group was 0.61 (95% CI: 0.46-0.82, P = .001) for thromboembolism and was 1.05 (95% CI: 0.71-1.56, P = 0.81) for major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This observational study suggests that the benefits and risks of continuing OAC therapy after CA for AF differ based on the patient's CHADS2 score. The risk of major bleeding due to OAC continuation seems to outweigh the risk reduction of thromboembolism in patients with lower thromboembolic risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38117227/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38117227</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad798>10.1093/eurheartj/ehad798</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38117227</guid>
<pubDate>Wed, 20 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Koshiro Kanaoka</dc:creator>
<dc:creator>Taku Nishida</dc:creator>
<dc:creator>Yoshitaka Iwanaga</dc:creator>
<dc:creator>Michikazu Nakai</dc:creator>
<dc:creator>Reina Tonegawa-Kuji</dc:creator>
<dc:creator>Yuichi Nishioka</dc:creator>
<dc:creator>Tomoya Myojin</dc:creator>
<dc:creator>Katsuki Okada</dc:creator>
<dc:creator>Tatsuya Noda</dc:creator>
<dc:creator>Kengo Kusano</dc:creator>
<dc:creator>Yoshihiro Miyamoto</dc:creator>
<dc:creator>Yoshihiko Saito</dc:creator>
<dc:creator>Tomoaki Imamura</dc:creator>
<dc:date>2023-12-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks</dc:title>
<dc:identifier>pmid:38117227</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad798</dc:identifier>
</item>
<item>
<title>Left atrial appendage occlusion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38114751/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Dec 19. doi: 10.1038/s41569-023-00973-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38114751/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38114751</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00973-0>10.1038/s41569-023-00973-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38114751</guid>
<pubDate>Tue, 19 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jacqueline Saw</dc:creator>
<dc:date>2023-12-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Left atrial appendage occlusion</dc:title>
<dc:identifier>pmid:38114751</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00973-0</dc:identifier>
</item>
<item>
<title>Bone marrow adipocytes support fatty acid metabolism during MI-mediated emergency haematopoiesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38114750/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Dec 19. doi: 10.1038/s41569-023-00987-8. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38114750/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38114750</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00987-8>10.1038/s41569-023-00987-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38114750</guid>
<pubDate>Tue, 19 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-12-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Bone marrow adipocytes support fatty acid metabolism during MI-mediated emergency haematopoiesis</dc:title>
<dc:identifier>pmid:38114750</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00987-8</dc:identifier>
</item>
<item>
<title>Epigenetic control of vascular endothelial function revealed by multi-omics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38113245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 19:ehad820. doi: 10.1093/eurheartj/ehad820. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38113245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38113245</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad820>10.1093/eurheartj/ehad820</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38113245</guid>
<pubDate>Tue, 19 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Hywel Dunn-Davies</dc:creator>
<dc:creator>Tatiana Dudnakova</dc:creator>
<dc:creator>Andrew H Baker</dc:creator>
<dc:creator>Tijana Mitić</dc:creator>
<dc:date>2023-12-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Epigenetic control of vascular endothelial function revealed by multi-omics</dc:title>
<dc:identifier>pmid:38113245</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad820</dc:identifier>
</item>
<item>
<title>Epilepsy and the heart: can 'brain arrhythmia' lead to cardiac arrhythmias? Back to the basics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38113187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 19:ehad807. doi: 10.1093/eurheartj/ehad807. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38113187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38113187</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad807>10.1093/eurheartj/ehad807</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38113187</guid>
<pubDate>Tue, 19 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Guilherme L Fialho</dc:creator>
<dc:date>2023-12-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Epilepsy and the heart: can 'brain arrhythmia' lead to cardiac arrhythmias? Back to the basics</dc:title>
<dc:identifier>pmid:38113187</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad807</dc:identifier>
</item>
<item>
<title>Next step of 'epileptic heart'</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38113185/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 19:ehad809. doi: 10.1093/eurheartj/ehad809. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38113185/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38113185</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad809>10.1093/eurheartj/ehad809</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38113185</guid>
<pubDate>Tue, 19 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Yao Lu</dc:creator>
<dc:creator>Jie Wang</dc:creator>
<dc:creator>Qingwei Yu</dc:creator>
<dc:date>2023-12-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Next step of 'epileptic heart'</dc:title>
<dc:identifier>pmid:38113185</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad809</dc:identifier>
</item>
<item>
<title>Age-Induced Accumulation of Succinate Promotes Cardiac Fibrogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38112098/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>CONCLUSIONS: Our findings indicate that targeting metabolic dysregulation has significant implications for the treatment of age-related cardiac fibrosis and diastolic dysfunction. We further demonstrate a novel mechanism by which succinate induces fibroblast activation and apoptosis resistance by promoting PKM2 dimerization. Hence, inhibiting succinate generation or blocking its downstream effects is potentially a promising new strategy for slowing the heart aging.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Dec 19. doi: 10.1161/CIRCRESAHA.123.323651. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Age-related cardiac fibrosis is a risk factor for heart failure and a marker for heart aging. However, the mechanisms underlying age-related cardiac fibrosis remain unclear. Ischemia and hypoxia are inevitable events in the aging process, which are direct causes of mitochondrial dysfunction and metabolic alterations. In this study, we identified metabolic changes and determined the mechanisms by which succinate (a tricarboxylic acid cycle intermediate) accumulation promotes fibroblast activation and apoptosis resistance in the aging heart. We also assessed its significance in relation to cardiac fibrosis and diastolic dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We first investigated how aging promotes persistent cardiac fibrosis. Following this, the metabolic alterations of the aging heart were identified by untargeted metabolomics, and the succinate level was verified via quantitative analysis. Furthermore, the correlations between succinate and fibrosis or diastolic dysfunction in older mice/people were assessed. We also described the role of succinate and its receptor SUCNR1/GPR91 in establishing a fibrosis network during diastolic dysfunction with age using SUCNR1<sup>-/-</sup> mouse model and an AAV9-based approach. We further identified the specific mechanisms involved in PKM2 dimerization, which regulate fibroblast activation and apoptosis resistance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We demonstrated that aging promotes fibrogenesis and diastolic dysfunction, which are linked to fibroblast activation and apoptosis resistance in the heart. Succinate levels were correlated with diastolic dysfunction and cardiac fibrosis in older mice and people. Functionally, succinate promoted fibroblast activation and apoptosis resistance, which aggravate cardiac fibrosis formation in both young and old mice. This was attributed to the ability of succinate to stimulate PKM2 dimerization via succinate receptor SUCNR1. Furthermore, dimeric PKM2 translocated to the nucleus and mitochondria, where it promoted fibroblast activation and apoptosis resistance, respectively. Accumulated PKM2 in the nucleus interacted with HIF-1α, increasing the DNA binding of HIF-1α and the expression of fibrogenic genes, resulting in fibroblast activation. In the mitochondria, accumulated PKM2 phosphorylated VDAC1 at T93 and increased VDAC1 degradation by promoting SYVN1-based E3 ligase binding to VDAC1, which is associated with increased apoptosis resistance and fibrosis persistence. We found that targeting succinate accumulation by metformin can inhibit fibroblast activation and apoptosis resistance in mice, which is a potential strategy to control age-related cardiac fibrosis and diastolic dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings indicate that targeting metabolic dysregulation has significant implications for the treatment of age-related cardiac fibrosis and diastolic dysfunction. We further demonstrate a novel mechanism by which succinate induces fibroblast activation and apoptosis resistance by promoting PKM2 dimerization. Hence, inhibiting succinate generation or blocking its downstream effects is potentially a promising new strategy for slowing the heart aging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38112098/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38112098</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323651>10.1161/CIRCRESAHA.123.323651</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38112098</guid>
<pubDate>Tue, 19 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Ziwen Wang</dc:creator>
<dc:creator>Shu Yang</dc:creator>
<dc:creator>Zheng Ping</dc:creator>
<dc:creator>Yaqi Li</dc:creator>
<dc:creator>Ting Jiang</dc:creator>
<dc:creator>Xin Zheng</dc:creator>
<dc:creator>Ziyuan Zhang</dc:creator>
<dc:creator>Guan Wang</dc:creator>
<dc:creator>Zhaochuan Liu</dc:creator>
<dc:creator>Haimei Sun</dc:creator>
<dc:creator>Qi Zhang</dc:creator>
<dc:creator>Heyang Zhang</dc:creator>
<dc:creator>Yang Gao</dc:creator>
<dc:creator>Youxin Feng</dc:creator>
<dc:creator>Xixi Liu</dc:creator>
<dc:creator>Lizhuang Han</dc:creator>
<dc:creator>Shiqi Lin</dc:creator>
<dc:creator>Xiaowei Zhang</dc:creator>
<dc:creator>Mengmeng Song</dc:creator>
<dc:creator>Tong Liu</dc:creator>
<dc:creator>Meng Tang</dc:creator>
<dc:creator>Chenan Liu</dc:creator>
<dc:creator>Hailun Xie</dc:creator>
<dc:creator>Guotian Ruan</dc:creator>
<dc:creator>Ming Yang</dc:creator>
<dc:creator>Yue Chen</dc:creator>
<dc:creator>Xiaohan Yuan</dc:creator>
<dc:creator>Dongying Wang</dc:creator>
<dc:creator>Xiaoli Zhang</dc:creator>
<dc:creator>Chenyang Wang</dc:creator>
<dc:creator>Zhongyong Jiang</dc:creator>
<dc:creator>Ying Xu</dc:creator>
<dc:creator>Long Chen</dc:creator>
<dc:creator>Li Deng</dc:creator>
<dc:creator>Bo Wu</dc:creator>
<dc:creator>Deshan Zhou</dc:creator>
<dc:creator>Xuebin Cao</dc:creator>
<dc:creator>Hanping Shi</dc:creator>
<dc:creator>Tingyi Sun</dc:creator>
<dc:date>2023-12-19</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Age-Induced Accumulation of Succinate Promotes Cardiac Fibrogenesis</dc:title>
<dc:identifier>pmid:38112098</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323651</dc:identifier>
</item>
<item>
<title>Cardiac Catheterization Laboratory Management of the Comatose Adult Patient With an Out-of-Hospital Cardiac Arrest: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38112086/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>Out-of-hospital cardiac arrest is a leading cause of death, accounting for ≈50% of all cardiovascular deaths. The prognosis of such individuals is poor, with &lt;10% surviving to hospital discharge. Survival with a favorable neurologic outcome is highest among individuals who present with a witnessed shockable rhythm, received bystander cardiopulmonary resuscitation, achieve return of spontaneous circulation within 15 minutes of arrest, and have evidence of ST-segment elevation on initial ECG after...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Dec 19. doi: 10.1161/CIR.0000000000001199. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Out-of-hospital cardiac arrest is a leading cause of death, accounting for ≈50% of all cardiovascular deaths. The prognosis of such individuals is poor, with &lt;10% surviving to hospital discharge. Survival with a favorable neurologic outcome is highest among individuals who present with a witnessed shockable rhythm, received bystander cardiopulmonary resuscitation, achieve return of spontaneous circulation within 15 minutes of arrest, and have evidence of ST-segment elevation on initial ECG after return of spontaneous circulation. The cardiac catheterization laboratory plays an important role in the coordinated Chain of Survival for patients with out-of-hospital cardiac arrest. The catheterization laboratory can be used to provide diagnostic, therapeutic, and resuscitative support after sudden cardiac arrest from many different cardiac causes, but it has a unique importance in the treatment of cardiac arrest resulting from underlying coronary artery disease. Over the past few years, numerous trials have clarified the role of the cardiac catheterization laboratory in the management of resuscitated patients or those with ongoing cardiac arrest. This scientific statement provides an update on the contemporary approach to managing resuscitated patients or those with ongoing cardiac arrest.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38112086/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38112086</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001199>10.1161/CIR.0000000000001199</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38112086</guid>
<pubDate>Tue, 19 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jacqueline E Tamis-Holland</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>Nicholas J Johnson</dc:creator>
<dc:creator>Karl B Kern</dc:creator>
<dc:creator>Alejandro Lemor</dc:creator>
<dc:creator>Peter J Mason</dc:creator>
<dc:creator>Mary Rodgers</dc:creator>
<dc:creator>Gregory W Serrao</dc:creator>
<dc:creator>Demetris Yannopoulos</dc:creator>
<dc:creator>Interventional Cardiovascular Care Committee and the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2023-12-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Catheterization Laboratory Management of the Comatose Adult Patient With an Out-of-Hospital Cardiac Arrest: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38112086</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001199</dc:identifier>
</item>
<item>
<title>Author Correction: Optical coherence tomography in coronary atherosclerosis assessment and intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38110566/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231222090757&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Dec 18. doi: 10.1038/s41569-023-00982-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38110566/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231222090757&v=2.18.0">38110566</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00982-z>10.1038/s41569-023-00982-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38110566</guid>
<pubDate>Tue, 19 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Makoto Araki</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>Harold L Dauerman</dc:creator>
<dc:creator>Shiro Uemura</dc:creator>
<dc:creator>Jung-Sun Kim</dc:creator>
<dc:creator>Carlo Di Mario</dc:creator>
<dc:creator>Thomas W Johnson</dc:creator>
<dc:creator>Giulio Guagliumi</dc:creator>
<dc:creator>Adnan Kastrati</dc:creator>
<dc:creator>Michael Joner</dc:creator>
<dc:creator>Niels Ramsing Holm</dc:creator>
<dc:creator>Fernando Alfonso</dc:creator>
<dc:creator>William Wijns</dc:creator>
<dc:creator>Tom Adriaenssens</dc:creator>
<dc:creator>Holger Nef</dc:creator>
<dc:creator>Gilles Rioufol</dc:creator>
<dc:creator>Nicolas Amabile</dc:creator>
<dc:creator>Geraud Souteyrand</dc:creator>
<dc:creator>Nicolas Meneveau</dc:creator>
<dc:creator>Edouard Gerbaud</dc:creator>
<dc:creator>Maksymilian P Opolski</dc:creator>
<dc:creator>Nieves Gonzalo</dc:creator>
<dc:creator>Guillermo J Tearney</dc:creator>
<dc:creator>Brett Bouma</dc:creator>
<dc:creator>Aaron D Aguirre</dc:creator>
<dc:creator>Gary S Mintz</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Christos V Bourantas</dc:creator>
<dc:creator>Lorenz Räber</dc:creator>
<dc:creator>Sebastiano Gili</dc:creator>
<dc:creator>Kyoichi Mizuno</dc:creator>
<dc:creator>Shigeki Kimura</dc:creator>
<dc:creator>Toshiro Shinke</dc:creator>
<dc:creator>Myeong-Ki Hong</dc:creator>
<dc:creator>Yangsoo Jang</dc:creator>
<dc:creator>Jin Man Cho</dc:creator>
<dc:creator>Bryan P Yan</dc:creator>
<dc:creator>Italo Porto</dc:creator>
<dc:creator>Giampaolo Niccoli</dc:creator>
<dc:creator>Rocco A Montone</dc:creator>
<dc:creator>Vikas Thondapu</dc:creator>
<dc:creator>Michail I Papafaklis</dc:creator>
<dc:creator>Lampros K Michalis</dc:creator>
<dc:creator>Harmony Reynolds</dc:creator>
<dc:creator>Jacqueline Saw</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Giora Weisz</dc:creator>
<dc:creator>Mario Iannaccone</dc:creator>
<dc:creator>Tommaso Gori</dc:creator>
<dc:creator>Konstantinos Toutouzas</dc:creator>
<dc:creator>Taishi Yonetsu</dc:creator>
<dc:creator>Yoshiyasu Minami</dc:creator>
<dc:creator>Masamichi Takano</dc:creator>
<dc:creator>O Christopher Raffel</dc:creator>
<dc:creator>Osamu Kurihara</dc:creator>
<dc:creator>Tsunenari Soeda</dc:creator>
<dc:creator>Tomoyo Sugiyama</dc:creator>
<dc:creator>Hyung Oh Kim</dc:creator>
<dc:creator>Tetsumin Lee</dc:creator>
<dc:creator>Takumi Higuma</dc:creator>
<dc:creator>Akihiro Nakajima</dc:creator>
<dc:creator>Erika Yamamoto</dc:creator>
<dc:creator>Krzysztof L Bryniarski</dc:creator>
<dc:creator>Luca Di Vito</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Francesco Fracassi</dc:creator>
<dc:creator>Michele Russo</dc:creator>
<dc:creator>Lena M Seegers</dc:creator>
<dc:creator>Iris McNulty</dc:creator>
<dc:creator>Sangjoon Park</dc:creator>
<dc:creator>Marc Feldman</dc:creator>
<dc:creator>Javier Escaned</dc:creator>
<dc:creator>Francesco Prati</dc:creator>
<dc:creator>Eloisa Arbustini</dc:creator>
<dc:creator>Fausto J Pinto</dc:creator>
<dc:creator>Ron Waksman</dc:creator>
<dc:creator>Hector M Garcia-Garcia</dc:creator>
<dc:creator>Akiko Maehara</dc:creator>
<dc:creator>Ziad Ali</dc:creator>
<dc:creator>Aloke V Finn</dc:creator>
<dc:creator>Renu Virmani</dc:creator>
<dc:creator>Annapoorna S Kini</dc:creator>
<dc:creator>Joost Daemen</dc:creator>
<dc:creator>Teruyoshi Kume</dc:creator>
<dc:creator>Kiyoshi Hibi</dc:creator>
<dc:creator>Atsushi Tanaka</dc:creator>
<dc:creator>Takashi Akasaka</dc:creator>
<dc:creator>Takashi Kubo</dc:creator>
<dc:creator>Satoshi Yasuda</dc:creator>
<dc:creator>Kevin Croce</dc:creator>
<dc:creator>Juan F Granada</dc:creator>
<dc:creator>Amir Lerman</dc:creator>
<dc:creator>Abhiram Prasad</dc:creator>
<dc:creator>Evelyn Regar</dc:creator>
<dc:creator>Yoshihiko Saito</dc:creator>
<dc:creator>Mullasari Ajit Sankardas</dc:creator>
<dc:creator>Vijayakumar Subban</dc:creator>
<dc:creator>Neil J Weissman</dc:creator>
<dc:creator>Yundai Chen</dc:creator>
<dc:creator>Bo Yu</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Peter Barlis</dc:creator>
<dc:creator>Nick E J West</dc:creator>
<dc:creator>Armin Arbab-Zadeh</dc:creator>
<dc:creator>Jong Chul Ye</dc:creator>
<dc:creator>Jouke Dijkstra</dc:creator>
<dc:creator>Hang Lee</dc:creator>
<dc:creator>Jagat Narula</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Sunao Nakamura</dc:creator>
<dc:creator>Tsunekazu Kakuta</dc:creator>
<dc:creator>James Fujimoto</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>Ik-Kyung Jang</dc:creator>
<dc:date>2023-12-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Author Correction: Optical coherence tomography in coronary atherosclerosis assessment and intervention</dc:title>
<dc:identifier>pmid:38110566</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00982-z</dc:identifier>
</item>





























</channel>
</rss>